Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-102 Transdermal GFR Monitoring System Phase 3 Study
CTR20221860Phase 3Completed
- Sponsor
- MediBeacon
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of relmapirazin in chronic kidney disease (CKD) and nephropathy, sponsored by MediBeacon. Primary endpoint: Agreement of transdermal fluorescence GFR with plasma MB-102 GFR (P30 value). Started Aug 2022; status: completed.
02
Drugs
relmapirazin
03
Conditions
chronic kidney disease (CKD)nephropathy
Beyond the preview
Go deeper on CTR20221860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221860.